Pharma Meets Cannabis Ahead Of Potential Cannabis Rescheduling, Here’s More About New Partnership

InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) is teaming up with Cannasoul R&D Ltd., a cannabis-focused research and analytics firm.

What Happened

Under the deal, the Israel-based InterCure agreed to buy a 28% ownership stake in Cannasoul. InterCure also has an option to boost its stake in the company to 51% over the next two years.

Moreover, Prof. Dedi Meiri, founder of Cannasoul and a cannabis researcher at the Technion – Israel Institute of Technology, is expected to be named chairperson of the company’s Scientific Advisory Board, to be established by the company’s board of directors.

Why It Matters

The partnership combines InterCure’s global pharmaceutical platform with Cannasoul’s analytics and scientific innovation.

The two companies plan to work together to research, develop, and bring evidence-based cannabis therapies to market.

“By combining Cannasoul’s established research capabilities with InterCure’s pharmaceutical-grade platform and under the scientific advisory of Prof. Meiri, we plan to accelerate the development of next-generation cannabis therapeutics, expand our international footprint, and drive long-term value for patients and shareholders alike,” Alex Rabinovitch, InterCure’s CEO, said.

What’s Next

The collaboration comes amidst President Donald Trump’s administration reportedly looking at reclassifying cannabis.

Trump told reporters in August at a news conference in the White House briefing room that rescheduling marijuana from a Schedule 1 drug to a Schedule 3 drug is something they are “looking at” and that it’s a “very complicated subject,” as reported by ABC News.

Cannabis rescheduling is expected to set up opportunities nationwide for international operators like InterCure.